Background
Background The extentto which anti-
The extentto which antipsychotics improve patients' well-being is psychotics improve patients' well-being is uncertain. uncertain.
Aims Aims To examine psychopathology and
To examine psychopathology and patient-rated functioning and well-beingin patient-rated functioning and well-beingin patients treated with risperidone. patients treated with risperidone.
Method Method In a1-year, open-label, inter-
In a1-year, open-label, international multicentre trial of long-acting national multicentre trial of long-acting risperidone in 615 stable adult patients risperidone in 615 stable adult patients with schizophrenia, self-rated functioning with schizophrenia, self-rated functioning and well-being were measured every 3 and well-being were measured every 3 months using the Short Form 36 -item months using the Short Form 36 -item questionnaire (SF^36).Psychopathology questionnaire (SF^36).Psychopathology was quantified using the Positive and was quantified using the Positive and Negative Syndrome Scale (PANSS). Negative Syndrome Scale (PANSS).
Results

Results Significant improvements were
Significant improvements were found on the SF^36 mental compo found on the SF^36 mental component nent summaryscore andvitalityandsocialfuncsummaryscore andvitalityandsocialfunctioningscales.PANSSandmentalcomponent tioningscales.PANSSandmentalcomponent summaryscoresweremoderatelycorrelated. summaryscoresweremoderatelycorrelated.
Conclusions Conclusions Patient-reported func-
Patient-reported functioning and well-being appear to differ tioning and well-being appear to differ from investigator-rated psychotic from investigator-rated psychotic symptoms.Patient-rated well-being should symptoms.Patient-rated well-being should be assessed with symptoms to help be assessed with symptoms to help measure treatment outcomes. measure treatment outcomes.
The vulnerability of patients with long-term The vulnerability of patients with long-term mental illness to reduced levels of satisfacmental illness to reduced levels of satisfaction with their living situation, family and tion with their living situation, family and social relations, leisure activities, work, social relations, leisure activities, work, finances, safety and health, compared with finances, safety and health, compared with the general population, has been recognised the general population, has been recognised for many years (Lehman for many years (Lehman et al et al, 1982) . , 1982). Although there have been advances in treatAlthough there have been advances in treatment following the introduction into clinment following the introduction into clinical practice of the novel antipsychotic ical practice of the novel antipsychotic drugs, concerns about patients' functioning drugs, concerns about patients' functioning and well-being are still valid today and well-being are still valid today (Bengtsson-Tops & Hansson, 1999; Doyle (Bengtsson-Tops & Hansson, 1999; Doyle et al et al, 1999; Aksaray , 1999; Aksaray et al et al, 2002 Aksaray et al et al, ), parti-, 2002 , particularly in those with residual symptoms cularly in those with residual symptoms and in those who have not achieved an and in those who have not achieved an optimal response to treatment (Kane, optimal response to treatment (Kane, 1999) . Improvement in these outcomes is 1999) . Improvement in these outcomes is therefore an important dimension of therefore an important dimension of successful treatment alongside symptom successful treatment alongside symptom improvement. Our study examined selfimprovement. Our study examined selfrated functioning and well-being among rated functioning and well-being among clinically stable patients with schizophrenia clinically stable patients with schizophrenia during a year-long trial that evaluated during a year-long trial that evaluated the long-term safety and efficacy of longthe long-term safety and efficacy of longacting risperidone, and investigated the acting risperidone, and investigated the relationship between subjective functionrelationship between subjective functioning, well-being and objective measures of ing, well-being and objective measures of schizophrenia symptoms. schizophrenia symptoms.
METHOD METHOD
An open-label, international multicentre An open-label, international multicentre trial was conducted to evaluate the longtrial was conducted to evaluate the longterm outcome of treatment with long-acting term outcome of treatment with long-acting risperidone given as an intramuscular injecrisperidone given as an intramuscular injection every 2 weeks, for 1 year. A more tion every 2 weeks, for 1 year. A more detailed description of the study methoddetailed description of the study methodology is provided elsewhere (Fleischhacker ology is provided elsewhere (Fleischhacker et al et al, 2003) .
, 2003).
Participants Participants
Eligible patients were at least 18 years old Eligible patients were at least 18 years old and had a DSM-IV diagnosis of schizoand had a DSM-IV diagnosis of schizophrenia (American Psychiatric Association, phrenia (American Psychiatric Association, 1994) . They were required to be sympt-1994). They were required to be symptomatically stable, as judged by the treating omatically stable, as judged by the treating physician, be receiving a stable dose of an physician, be receiving a stable dose of an antipsychotic drug for at least 4 weeks antipsychotic drug for at least 4 weeks before the trial and be in good general phybefore the trial and be in good general physical health. The main exclusion criteria sical health. The main exclusion criteria were substance dependence, a history of were substance dependence, a history of tardive dyskinesia, neuroleptic malignant tardive dyskinesia, neuroleptic malignant syndrome or clinically significant physical syndrome or clinically significant physical abnormalities. Patients who had been abnormalities. Patients who had been treated with clozapine within 2 months of treated with clozapine within 2 months of entry into the trial or with a conventional entry into the trial or with a conventional depot antipsychotic drug within one treatdepot antipsychotic drug within one treatment cycle were also ineligible. ment cycle were also ineligible.
Study medication Study medication
After a 2-week run-in period during which After a 2-week run-in period during which antipsychotic agents other than risperidone antipsychotic agents other than risperidone were discontinued, patients were started on were discontinued, patients were started on oral risperidone at a daily dosage of 1-6 mg oral risperidone at a daily dosage of 1-6 mg based on the judgement of the treating phybased on the judgement of the treating physician. The oral dosage was used as a guide sician. The oral dosage was used as a guide to the starting dose of long-acting risperito the starting dose of long-acting risperidone of 25 mg, 50 mg or 75 mg. Suppledone of 25 mg, 50 mg or 75 mg. Supplementation with oral risperidone was given mentation with oral risperidone was given for 2-3 weeks following the first injection for 2-3 weeks following the first injection of long-acting risperidone to provide antiof long-acting risperidone to provide antipsychotic coverage during the 3-week psychotic coverage during the 3-week latency period after the first injection latency period after the first injection (Eeredekens (Eeredekens et al et al, 2004) . Concomitant , 2004) . Concomitant medications that could be initiated or conmedications that could be initiated or continued, at the discretion of the investigator, tinued, at the discretion of the investigator, were those to assist sleep, anti-Parkinsonian were those to assist sleep, anti-Parkinsonian agents, antidepressants, mood stabilisers, agents, antidepressants, mood stabilisers, propranolol for akathisia and benzodiazepropranolol for akathisia and benzodiazepines for agitation and insomnia. pines for agitation and insomnia.
Measures Measures
Both the Positive and Negative Syndrome Both the Positive and Negative Syndrome Scale (PANSS; Kay Scale (PANSS; Kay et al et al, 1987; Kay & , 1987; Kay & Singh, 1989) , which was the primary meaSingh, 1989), which was the primary measure of treatment efficacy, and the Medical sure of treatment efficacy, and the Medical Outcomes Study Short Form 36-item quesOutcomes Study Short Form 36-item questionnaire (SF-36; Ware tionnaire (SF-36; Ware et al et al, 1993 Ware et al et al, ), which , 1993 , which measures patient-rated functioning and measures patient-rated functioning and well-being, were administered every 3 well-being, were administered every 3 months. The SF-36 is a multipurpose months. The SF-36 is a multipurpose generic measure of functional health and generic measure of functional health and well-being with psychometrically based well-being with psychometrically based physical and mental health summary physical and mental health summary measures, comprising eight domains which measures, comprising eight domains which assess the following quality of life assess the following quality of life parameters: parameters: Scores range from 0 to 100, with the Scores range from 0 to 100, with the higher scores indicating a better quality of higher scores indicating a better quality of life. From these eight domains, a physical life. From these eight domains, a physical component summary score (composed of component summary score (composed of items a-d) and a mental component items a-d) and a mental component summary score (composed of items e-h) summary score (composed of items e-h) were calculated and compared with benchwere calculated and compared with benchmark scores from a general population mark scores from a general population (Ware, 2003) . Scores above or below 50 (Ware, 2003) . Scores above or below 50 represent quality of life above or below represent quality of life above or below the population average, respectively. the population average, respectively. Patients completed the questionnaire prior Patients completed the questionnaire prior to being interviewed by the investigator. A to being interviewed by the investigator. A 1-month recall was used for all questions. 1-month recall was used for all questions. The SF-36 has been found to be suitable The SF-36 has been found to be suitable for use in multinational studies (Ware for use in multinational studies (Ware et et al al, 1998) .
, 1998). The Structured Clinical Interview for The Structured Clinical Interview for PANSS (Kay PANSS (Kay et al et al, 1987) was used to rate , 1987) was used to rate schizophrenia symptoms. In addition to schizophrenia symptoms. In addition to the total PANSS score (sum of all 30 items, the total PANSS score (sum of all 30 items, maximum score 7 per item), five sub-scales maximum score 7 per item), five sub-scales were calculated based on the findings of were calculated based on the findings of Marder Marder et al et al (1997) . These sub-scales were: (1997). These sub-scales were:
(a) (a) positive symptoms positive symptoms: delusions, halluci-: delusions, hallucinatory behaviour, grandiosity, susnatory behaviour, grandiosity, suspiciousness (items 1, 3, 5 and 6 on the piciousness (items 1, 3, 5 and 6 on the positive sub-scale); stereotyped positive sub-scale); stereotyped thinking (item 7 on the negative subthinking (item 7 on the negative subscale); somatic concern, unusual scale); somatic concern, unusual thought content, lack of judgement thought content, lack of judgement and insight (items 1, 9 and 12 on the and insight (items 1, 9 and 12 on the general psychopathology sub-scale); general psychopathology sub-scale); (b) (b) negative symptoms negative symptoms: blunted affect, : blunted affect, emotional withdrawal, poor rapport, emotional withdrawal, poor rapport, passive social withdrawal, lack of sponpassive social withdrawal, lack of spontaneity (items 1, 2, 3, 4 and 6 on the taneity (items 1, 2, 3, 4 and 6 on the negative sub-scale); motor retardation, negative sub-scale); motor retardation, active social avoidance (items 7 and active social avoidance (items 7 and 16 on the general psychopathology 16 on the general psychopathology sub-scale); sub-scale); (c) (c) disorganised thoughts disorganised thoughts: conceptual : conceptual disorganisation (item 2 on the positive disorganisation (item 2 on the positive sub-scale); difficulty in abstract sub-scale); difficulty in abstract thinking (item 5 on the negative subthinking (item 5 on the negative subscale); mannerisms and posturing, scale); mannerisms and posturing, disorientation, poor attention, disturdisorientation, poor attention, disturbance of volition, preoccupation bance of volition, preoccupation (items 5, 10, 11, 13 and 15 on the (items 5, 10, 11, 13 and 15 on the general psychopathology sub-scale); general psychopathology sub-scale);
uncontrolled hostility/excitement: exci-: excitement, hostility (items 4 and 7 of the tement, hostility (items 4 and 7 of the positive sub-scale); uncooperativeness positive sub-scale); uncooperativeness and poor impulse control (items 8 and and poor impulse control (items 8 and 14 on the general psychopathology 14 on the general psychopathology sub-scale); sub-scale); (e) (e) anxiety/depression anxiety/depression: anxiety, guilt feel-: anxiety, guilt feelings, tension, depression (items 2, 3, 4 ings, tension, depression (items 2, 3, 4 and 6 on the general psychopathology and 6 on the general psychopathology sub-scale). sub-scale).
Sample Sample
A total of 615 patients with schizophrenia A total of 615 patients with schizophrenia were recruited into this trial (422 men, were recruited into this trial (422 men, 193 women). The majority (92%) of them 193 women). The majority (92%) of them were White, and their mean age was 42 were White, and their mean age was 42 years (s.e. years (s.e.¼0.6, range 18-84). The mean 0.6, range 18-84). The mean PANSS total score at baseline was 67.1 PANSS total score at baseline was 67.1 (s.e. (s.e.¼0.8). Eighty-seven per cent of the 0.8). Eighty-seven per cent of the total cohort completed the first 3 months, total cohort completed the first 3 months, and 65% completed the 1-year trial period. and 65% completed the 1-year trial period. Tolerability, safety and efficacy have been Tolerability, safety and efficacy have been reported elsewhere (Fleischhacker reported elsewhere (Fleischhacker et al et al, , 2003) , and suggest that in schizophrenia 2003), and suggest that in schizophrenia patients with stable symptoms can achieve patients with stable symptoms can achieve further improvement in terms of both safety further improvement in terms of both safety and efficacy by having their medication and efficacy by having their medication switched to long-acting risperidone. switched to long-acting risperidone.
Statistical analysis Statistical analysis
The primary analysis of the study explored The primary analysis of the study explored changes in self-rated functioning and wellchanges in self-rated functioning and wellbeing from baseline at 12 weeks, 24 weeks, being from baseline at 12 weeks, 24 weeks, 36 weeks and 50 weeks and at end-point. 36 weeks and 50 weeks and at end-point. Changes from baseline in self-rated funcChanges from baseline in self-rated functioning and well-being, as measured by tioning and well-being, as measured by the SF-36, were analysed for each measurethe SF-36, were analysed for each measurement point and for the last observation for ment point and for the last observation for each patient using a paired samples each patient using a paired samples t t-test. -test. Differences on the SF-36 between popuDifferences on the SF-36 between population norms and study participants are exlation norms and study participants are expressed as effect size scores using Cohen's pressed as effect size scores using Cohen's formula (Cohen, 1976) , which consists of formula (Cohen, 1976) , which consists of subtracting the mean differences of the subtracting the mean differences of the two groups and dividing it by the pooled two groups and dividing it by the pooled standard deviation. Cohen (1976) has standard deviation. Cohen (1976) has termed effect sizes of 0.20-0.50 as small, termed effect sizes of 0.20-0.50 as small, 0.50-0.80 as medium and greater than 0.50-0.80 as medium and greater than 0.80 as large. For example, an effect size 0.80 as large. For example, an effect size of 0.20 corresponds to the difference of 0.20 corresponds to the difference between the heights of 15-year-old and between the heights of 15-year-old and 16-year-old girls in the USA, an effect size 16-year-old girls in the USA, an effect size of 0.50 corresponds to the difference of 0.50 corresponds to the difference between the heights of 14-year-old and between the heights of 14-year-old and 18-year-old girls and an effect size of 0.80 18-year-old girls and an effect size of 0.80 corresponds to the difference between the corresponds to the difference between the heights of 13-year-old and 18-year-old girls heights of 13-year-old and 18-year-old girls (Cohen, 1976) . (Cohen, 1976) .
A second planned analysis examined A second planned analysis examined the overlap of self-rated functioning and the overlap of self-rated functioning and well-being as measured by the four SF-36 well-being as measured by the four SF-36 mental health domains and the mental mental health domains and the mental component summary scores, and psychocomponent summary scores, and psychopathology as measured by the five PANSS pathology as measured by the five PANSS sub-scale scores. This was done by examinsub-scale scores. This was done by examining correlations of the measures and then ing correlations of the measures and then by maximum likelihood factor analysis by maximum likelihood factor analysis with promax rotation. The number of with promax rotation. The number of factors was determined by examining the factors was determined by examining the scree plots. Factor analysis permitted a test scree plots. Factor analysis permitted a test of the extent to which the PANSS sub-scale of the extent to which the PANSS sub-scale scores and SF-36 mental health domain scores and SF-36 mental health domain scores overlapped and the goodness of fit scores overlapped and the goodness of fit of the factor model obtained. Root mean of the factor model obtained. Root mean square error of approximation (RMSEA) square error of approximation (RMSEA) was used to indicate the goodness of fit; was used to indicate the goodness of fit; values below 0.1 are considered to be a values below 0.1 are considered to be a 'good' fit and those below 0.05 a 'very 'good' fit and those below 0.05 a 'very good' fit (Steiger, 1989) . good' fit (Steiger, 1989) .
RESULTS RESULTS
Self-rated functioning and Self-rated functioning and well-being at baseline and well-being at baseline and comparison with norms comparison with norms Table 1 shows the mean, standard devia- Table 1 shows the mean, standard deviation and normalised scores at baseline. tion and normalised scores at baseline. The internal consistency of the scales The internal consistency of the scales (Cronbach's (Cronbach's a a¼0.73-0.90) suggested that 0.73-0.90) suggested that there was good internal consistency of there was good internal consistency of responses. On the mental component sumresponses. On the mental component summary score participants were substantially mary score participants were substantially below norms by a large effect size of 0.80. below norms by a large effect size of 0.80. On the physical component summary score On the physical component summary score there was a much smaller difference from there was a much smaller difference from norms (effect size 0.22), but scores were norms (effect size 0.22), but scores were still below the norms. Almost half (49%) still below the norms. Almost half (49%) of the patients had scores above normal of the patients had scores above normal on the physical component summary on the physical component summary measure and 29% were above normal on measure and 29% were above normal on the mental component summary measure, the mental component summary measure, with few patients having values considerwith few patients having values considerably higher than normal levels. Except for ably higher than normal levels. Except for bodily pain and the physical component bodily pain and the physical component summary, scores on all the scales differed summary, scores on all the scales differed in effect size moderately to very strongly in effect size moderately to very strongly from the norms. from the norms.
Improvement in self-rated Improvement in self-rated functioning and well-being functioning and well-being during antipsychotic treatment during antipsychotic treatment Table 2 presents mean change on the SF-36 Table 2 presents mean change on the SF-36 domains and summary scores. On the phydomains and summary scores. On the physical health measures there was no signifisical health measures there was no significant change to end-point based on last cant change to end-point based on last value carried forward when examining all value carried forward when examining all participants. On the mental health participants. On the mental health measures there were significant improvemeasures there were significant improvements at all time points on the mental comments at all time points on the mental component summary, the vitality score and, ponent summary, the vitality score and, with the exception of week 12 ( with the exception of week 12 (P P¼0.08), 0.08), also on social functioning. On 'rolealso on social functioning. On 'roleemotional' there were significant emotional' there were significant improvements at all time points but not improvements at all time points but not at end-point derived by last observation at end-point derived by last observation carried forward analysis. carried forward analysis.
Association of self-rated Association of self-rated functioning and well-being functioning and well-being and PANSS and PANSS Table 3 shows the correlations of the Table 3 shows the correlations of the mental component summary, and the four mental component summary, and the four SF-36 mental health domain scores it com-SF-36 mental health domain scores it comprises, with the PANSS sub-scale scores at prises, with the PANSS sub-scale scores at baseline and the correlations among change baseline and the correlations among change from baseline to end-point on these from baseline to end-point on these measures. At baseline and on change, the measures. At baseline and on change, the highest correlations were found between highest correlations were found between the PANSS anxiety/depression scale and the PANSS anxiety/depression scale and the SF-36 domain 'general mental health'; the SF-36 domain 'general mental health'; at baseline the correlation coefficient was at baseline the correlation coefficient was r r¼7 70.53 and for change it was 0.53 and for change it was r r¼7 70.42. 0.42. Correlations of PANSS anxiety/depression Correlations of PANSS anxiety/depression with mental component summary were with mental component summary were 0.49 at baseline and 0.36 for the change 0.49 at baseline and 0.36 for the change scores. Despite the fact that both the total scores. Despite the fact that both the total PANSS score, as presented elsewhere PANSS score, as presented elsewhere (Fleischhacker (Fleischhacker et al et al, 2003) , and the mental , 2003), and the mental component summary score of the SF-36 component summary score of the SF-36 improved significantly over the course of improved significantly over the course of the trial, changes in the two measures were the trial, changes in the two measures were only moderately correlated ( only moderately correlated (r r¼7 70.4). 0.4).
To examine further the extent to which To examine further the extent to which the domains measured by the two instruthe domains measured by the two instruments overlapped, maximum likelihood ments overlapped, maximum likelihood factor analysis was conducted with promax factor analysis was conducted with promax rotation. The factor analysis included the rotation. The factor analysis included the five PANSS sub-scales and the four SF-36 five PANSS sub-scales and the four SF-36 mental health domains. Analyses of the mental health domains. Analyses of the baseline data and change scores both baseline data and change scores both produced two factors, one of which was produced two factors, one of which was associated with the five PANSS sub-scales, associated with the five PANSS sub-scales, the other with the four mental health the other with the four mental health domains of the SF-36. At baseline the domains of the SF-36. At baseline the factors cumulatively accounted for 47.2% factors cumulatively accounted for 47.2% of the variance and, for change to endof the variance and, for change to endpoint, for 39.5% of the variance. The point, for 39.5% of the variance. The correlation between the factors at baseline correlation between the factors at baseline was was r r¼7 70.34, suggesting that the SF-36 0.34, suggesting that the SF-36 and PANSS have an overlap of 12% at and PANSS have an overlap of 12% at baseline. For change to end-point the correbaseline. For change to end-point the correlation was lation was r r¼7 70.52, suggesting an overlap 0.52, suggesting an overlap of 27%. The factor plot presenting the of 27%. The factor plot presenting the results of the factor analysis for the baseline results of the factor analysis for the baseline measures is presented in Fig. 1 . The mental measures is presented in Fig. 1 . The mental health domains of the SF-36 were more health domains of the SF-36 were more tightly clustered than the sub-scales of the tightly clustered than the sub-scales of the PANSS. PANSS.
The RMSEA values for both baseline The RMSEA values for both baseline and change were 0.09, suggesting an accepand change were 0.09, suggesting an acceptable fit of the factors (Steiger, 1989) . The table fit of the factors (Steiger, 1989) . The results thus suggest that although the results thus suggest that although the PANSS (a measure of investigator-rated PANSS (a measure of investigator-rated psychopathology) and the mental health psychopathology) and the mental health domains of the SF-36 (a patient self-rating domains of the SF-36 (a patient self-rating measure of functioning and well-being) measure of functioning and well-being) are related, they do not overlap to a great are related, they do not overlap to a great extent, perhaps due to being different methextent, perhaps due to being different methods of assessment, with different strengths ods of assessment, with different strengths and weaknesses. This demonstrates the and weaknesses. This demonstrates the need for more than one method for the need for more than one method for the comprehensive assessment of outcomes. comprehensive assessment of outcomes.
DISCUSSION DISCUSSION
The principal aim of the treatment of The principal aim of the treatment of schizophrenia is to bring about a rapid schizophrenia is to bring about a rapid reduction of symptoms in the short term reduction of symptoms in the short term and to minimise the risk of relapse and and to minimise the risk of relapse and side-effects in the longer term. Traditional side-effects in the longer term. Traditional assessment instruments, such as PANSS assessment instruments, such as PANSS and the Clinical Global Impression (CGI; and the Clinical Global Impression (CGI; Guy, 2000) , are widely used -notably in Guy, 2000) , are widely used -notably in clinical trials -to measure and monitor obclinical trials -to measure and monitor objective changes in symptoms during treatjective changes in symptoms during treatment. These instruments, however, do not ment. These instruments, however, do not provide a wider picture of the subjective provide a wider picture of the subjective impact of treatment on the patient, particuimpact of treatment on the patient, particularly in terms of the effect on self-rated larly in terms of the effect on self-rated functioning and well-being. Achievement functioning and well-being. Achievement of the highest possible level of these paraof the highest possible level of these parameters is an outcome that is of major meters is an outcome that is of major importance, not only to patients, but also importance, not only to patients, but also to their family, caregivers and to payers. to their family, caregivers and to payers.
Despite the recognised importance of Despite the recognised importance of patient-reported outcomes, surprisingly patient-reported outcomes, surprisingly little information on such measures has little information on such measures has been collected in large samples of people been collected in large samples of people with severe mental illness treated with with severe mental illness treated with novel antipsychotic drugs. novel antipsychotic drugs.
Baseline illness severity Baseline illness severity and outcome and outcome
Even though our study recruited symptoEven though our study recruited symptomatically stable patients, baseline scores matically stable patients, baseline scores (particularly in the mental health domains) (particularly in the mental health domains) were significantly below population norms. were significantly below population norms. Improvements both in psychopathology Improvements both in psychopathology and in the mental health domains and the and in the mental health domains and the mental component summary score during mental component summary score during treatment with long-acting risperidone treatment with long-acting risperidone were apparent early in treatment and were were apparent early in treatment and were maintained throughout the long-term treatmaintained throughout the long-term treatment period. Given that the population in ment period. Given that the population in this study were required to be physically this study were required to be physically healthy, the physical component summary healthy, the physical component summary score and scores on its individual physical score and scores on its individual physical health domains (physical functioning, health domains (physical functioning, role -physical, bodily pain and general role -physical, bodily pain and general health) were high at baseline and health) were high at baseline and approached normative scores. Conseapproached normative scores. Consequently, the effect of treatment on the phyquently, the effect of treatment on the physical components of the SF-36 was modest sical components of the SF-36 was modest over the course of the study, which may over the course of the study, which may reflect the fact that treatment with longreflect the fact that treatment with longacting risperidone generally induces acting risperidone generally induces few side-effects that might interfere with few side-effects that might interfere with the subjective physical well-being of the subjective physical well-being of patients with schizophrenia. These findings patients with schizophrenia. These findings are consistent with the observed increments are consistent with the observed increments 13 4 13 4 Table 3  Table 3 Correlations of SF^36 mental health items and PANSS items at baseline and change from baseline to end-point ( Correlations of SF^36 mental health items and PANSS items at baseline and change from baseline to end-point (n n¼563) 563) Fig. 1 Factor plots in rotated factor space: baseline scores on five sub-scales of the Positive and Negative Factor plots in rotated factor space: baseline scores on five sub-scales of the Positive and Negative
Syndrome Scale (open circles) and four domains of the 36-item Short Form questionnaire (black circles: MH, Syndrome Scale (open circles) and four domains of the 36-item Short Form questionnaire (black circles: MH, mental health; RE, role^emotional; SF, social functioning; VI, vitality). mental health; RE, role^emotional; SF, social functioning; VI, vitality).
in a smaller double-blind, placeboin a smaller double-blind, placebocontrolled study, involving more severely controlled study, involving more severely symptomatic patients with schizophrenia symptomatic patients with schizophrenia treated with long-acting risperidone for a treated with long-acting risperidone for a shorter period (Nasrallah shorter period (Nasrallah et al et al, 2004) . , 2004).
Correlation results in the light
Correlation results in the light of previous studies of previous studies
In this study correlations between objective In this study correlations between objective symptom ratings and subjective ratings of symptom ratings and subjective ratings of functioning and well-being at baseline were functioning and well-being at baseline were only modest. Also, although patients in this only modest. Also, although patients in this trial improved both in terms of SF-36 trial improved both in terms of SF-36 mental health domain scores and the mental health domain scores and the PANSS scores (Fleischhacker PANSS scores (Fleischhacker et al et al, 2003 (Fleischhacker et al et al, ), , 2003 , there was only a moderate correlation there was only a moderate correlation between changes measured on the PANSS between changes measured on the PANSS and the SF-36. and the SF-36.
We are not aware of any other pubWe are not aware of any other published data on perceived functioning and lished data on perceived functioning and well-being, as measured by the SF-36, in well-being, as measured by the SF-36, in clinically stable patients with schizophrenia clinically stable patients with schizophrenia treated with novel antipsychotic drugs. The treated with novel antipsychotic drugs. The SF-36 was, however, used in another pub-SF-36 was, however, used in another published large-scale study in this area, conlished large-scale study in this area, conducted by Tunis ducted by Tunis et al et al (1999) in a large (1999) in a large cohort of people with schizophrenia who cohort of people with schizophrenia who participated in a clinical trial of olanzapine participated in a clinical trial of olanzapine v. v. haloperidol. The trial sample consisted of haloperidol. The trial sample consisted of patients who had clinically significant psypatients who had clinically significant psychosis and who had demonstrated less than chosis and who had demonstrated less than an optimal response to their previous median optimal response to their previous medication. The study found that the SF-36 cation. The study found that the SF-36 exhibited good reliability and validity exhibited good reliability and validity among people with schizophrenia. Tunis among people with schizophrenia. Tunis et al et al (1999) also found that, compared with (1999) also found that, compared with population norms, the study participants population norms, the study participants had marked deficits in the SF-36 domains had marked deficits in the SF-36 domains in general health, vitality, general mental in general health, vitality, general mental health, social functioning and in both health, social functioning and in both physical and emotional role limitation; physical and emotional role limitation; furthermore, correlations between the Brief furthermore, correlations between the Brief Psychiatric Rating Scale total score and the Psychiatric Rating Scale total score and the SF-36 domain scores were non-significant SF-36 domain scores were non-significant for all physical component scores and for all physical component scores and ranged from ranged from 7 70.20 to 0.20 to 7 70.31 for the 0.31 for the mental health domain scores (vitality, mental health domain scores (vitality, r r¼7 70.21; social functioning, 0.21; social functioning, r r¼7 70.29; 0.29; role -emotional, role -emotional, r r¼7 70.20; general mental 0.20; general mental health, health, r r¼7 70.31). Similar to our study, 0.31). Similar to our study, these correlations suggested -also in these correlations suggested -also in poorly responding patients -little overlap poorly responding patients -little overlap between the psychopathology measures between the psychopathology measures and the SF-36 mental health domains; and the SF-36 mental health domains; however, the association of each compohowever, the association of each component of the SF-36 with specific BPRS item nent of the SF-36 with specific BPRS item clusters was not examined, thus not clusters was not examined, thus not allowing more detailed examination of the allowing more detailed examination of the association of change in symptoms as rated association of change in symptoms as rated in a clinical interview and changes in in a clinical interview and changes in patients' perceived mental and physical patients' perceived mental and physical health. health.
These results support our finding that These results support our finding that patient-reported improvement in functionpatient-reported improvement in functioning and well-being is a different outcome ing and well-being is a different outcome dimension from investigator-rated improvedimension from investigator-rated improvement of psychopathology, which suggests ment of psychopathology, which suggests that it is advisable to use more than just that it is advisable to use more than just one method when assessing outcomes. one method when assessing outcomes.
Limitations Limitations
The major limitation of our study was that The major limitation of our study was that it did not have a control group, so that it did not have a control group, so that although improvements in well-being were although improvements in well-being were noted it is not possible to know whether noted it is not possible to know whether these changes would have occurred in the these changes would have occurred in the absence of treatment with long-acting risabsence of treatment with long-acting risperidone. Still, regardless of any potential peridone. Still, regardless of any potential drug effects, the finding that symptom drug effects, the finding that symptom improvement, as measured by an improvement, as measured by an observer-based rating scale, has little in observer-based rating scale, has little in common with subjectively experienced common with subjectively experienced functioning and well-being still stands. functioning and well-being still stands. Another limitation of the study is that the Another limitation of the study is that the SF-36 is a generic instrument used across SF-36 is a generic instrument used across all disease states, and its usefulness in all disease states, and its usefulness in schizophrenia is constrained by the fact that schizophrenia is constrained by the fact that it does not adequately cover the social it does not adequately cover the social domains, notably social functioning and domains, notably social functioning and psychosocial reintegration, that are relevant psychosocial reintegration, that are relevant outcomes in this illness. On the other hand, outcomes in this illness. On the other hand, the SF-36 is a patient-rated instrument that the SF-36 is a patient-rated instrument that is well validated and sensitive to changes in is well validated and sensitive to changes in the level of functioning in schizophrenia the level of functioning in schizophrenia (Russo (Russo et al et al, 1998; Tunis , 1998; Tunis et al et al, 1999) . It is , 1999). It is short, simple, practical and widely used, short, simple, practical and widely used, with associated normative data to enable with associated normative data to enable comparisons with the general population. comparisons with the general population.
Implications for further research Implications for further research
There is evolving evidence that in compariThere is evolving evidence that in comparison with conventional antipsychotics, novel son with conventional antipsychotics, novel antipsychotics are more effective in improvantipsychotics are more effective in improving health-related quality of life in patients ing health-related quality of life in patients with schizophrenia (Hamilton with schizophrenia (Hamilton et al et al, 2000; , 2000; Cook Cook et al et al, 2002; Karow & Naber, , 2002; Karow & Naber, 2002) . This may be a reflection of the effi-2002). This may be a reflection of the efficacy, tolerability and relapse prevention cacy, tolerability and relapse prevention benefits of these drugs over conventional benefits of these drugs over conventional drugs (Csernansky drugs (Csernansky et al et al, 2002; Sartorius , 2002; Sartorius et al et al, 2002 Sartorius et al et al, , 2003 Leucht , 2002 Leucht , , 2003 Leucht et al et al, 2003) . , 2003) . Whatever the cause of these improvements, Whatever the cause of these improvements, this outcome domain is very relevant to this outcome domain is very relevant to people with schizophrenia. people with schizophrenia.
Given the importance of health-related Given the importance of health-related quality of life, particularly among people quality of life, particularly among people with schizophrenia, and the apparent lack with schizophrenia, and the apparent lack of overlap between symptom improvement of overlap between symptom improvement and improvement in this domain, future and improvement in this domain, future clinical trials of antipsychotic medications clinical trials of antipsychotic medications should routinely apply measures such as should routinely apply measures such as the SF-36, optimally in conjunction with the SF-36, optimally in conjunction with a disease-specific, patient-rated instrument. a disease-specific, patient-rated instrument. Studies are also needed of the extent to Studies are also needed of the extent to which perceived functioning and well-being which perceived functioning and well-being are associated with longer-term outcomes are associated with longer-term outcomes such as relapse. In addition, more work is such as relapse. In addition, more work is needed in identifying which domains and needed in identifying which domains and measures of health-related quality of life measures of health-related quality of life are most germane to treating schizophrenia. are most germane to treating schizophrenia.
In summary, maintenance treatment In summary, maintenance treatment with long-acting risperidone appears to with long-acting risperidone appears to contribute to an improvement of outcomes contribute to an improvement of outcomes beyond a reduction of symptoms in patients beyond a reduction of symptoms in patients with schizophrenia. Clinically meaningful with schizophrenia. Clinically meaningful improvements were observed in our study improvements were observed in our study participants; these findings for self-rated participants; these findings for self-rated functioning and well-being are distinct functioning and well-being are distinct from symptomatic improvement. Therefrom symptomatic improvement. Therefore, patient functioning and well-being fore, patient functioning and well-being are relevant parameters to assess in are relevant parameters to assess in addition to symptom improvement. addition to symptom improvement. In symptomatically stable patients with schizophrenia treated with long-acting risperidone, statistically significant improvement was noted in the 36 -item Short risperidone, statistically significant improvement was noted in the 36-item Short Form (SF^36) mental health domains social functioning and vitality, and in the mental Form (SF^36) mental health domains social functioning and vitality, and in the mental component summary score. component summary score.
& & Improvements in psychopathology and perceived functioning and well-being Improvements in psychopathology and perceived functioning and well-being during antipsychotic treatment were only moderately associated, therefore both during antipsychotic treatment were only moderately associated, therefore both should be assessed when measuring treatment outcomes. should be assessed when measuring treatment outcomes.
LIMITATIONS LIMITATIONS
& & Without a control group, it is not possible to know whether changes in self-rated Without a control group, it is not possible to know whether changes in self-rated functioning and well-being would have occurred in the absence of treatment with functioning and well-being would have occurred in the absence of treatment with long-acting risperidone. long-acting risperidone. The SF^36 is a generic measure and may not adequately capture all areas of functioning and well-being that are relevant to people with schizophrenia; optimally, a functioning and well-being that are relevant to people with schizophrenia; optimally, a disease-specific instrument should be used alongside it. disease-specific instrument should be used alongside it.
& & The correlational design of the analyses leaves the potential for other unmeasured
The correlational design of the analyses leaves the potential for other unmeasured factors to contribute to, or confound, the observed relationships. factors to contribute to, or confound, the observed relationships.
